News

Antiangiogenic State May Be Key in Preeclampsia


 

MIAMI BEACH — Serum levels of soluble endoglin and soluble fms-like tyrosine kinase 1 are increased months before onset of clinical disease in patients with preeclampsia, Dr. Richard Levine said at the annual meeting of the Society for Maternal-Fetal Medicine.

The findings suggest that a circulating antiangiogenic state is important in the pathogenesis of this maternal syndrome, said Dr. Levine of the National Institute of Child Health and Human Development, Bethesda, Md.

“We believe that soluble endoglin [a cell surface receptor for the proangiogenic protein transforming growth factor-β and soluble fms-like tyrosine kinase 1 [an antiangiogenic factor that binds placental growth factor and vascular endothelial growth factor] act in concert to produce the maternal syndrome of preeclampsia,” he said.

A nested case-control study of the Calcium for Preeclampsia Prevention (CPEP) trial cohort of healthy nulliparas showed that compared with serum samples from gestational age-matched controls, the levels of these factors were significantly higher beginning 9–11 weeks before preterm preeclampsia. After preeclampsia onset, soluble endoglin (sEng) levels were almost fivefold higher (46 vs. 10 ng/mL) and soluble fms-like tyrosine kinase 1 (sFlt1) levels were nearly threefold higher (6,356 vs. 2,316 pg/mL). Placental growth factor (PlGF) levels were approximately fourfold lower (144 vs. 546 pg/mL), Dr. Levine said.

The findings were based on an analysis of 867 serum samples obtained from 120 controls; 120 patients with term preeclampsia; 72 patients with preterm preeclampsia; 9 patients with hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome; and 8 patients with eclampsia. In patients with term preeclampsia, sEng was increased beginning at 12–14 weeks, free PlGF decreased beginning at 9–11 weeks, and sFlt1 increased less than 5 weeks before preeclampsia onset. Alterations in angiogenic factors were more pronounced in early preeclampsia patients and in patients with preeclampsia plus a small-for-gestational age fetus, HELLP syndrome, or eclampsia, he noted.

Laboratory studies have suggested independent roles for both sEng and sFlt1 in the development of preeclampsia. The present study was designed to test the hypothesis that in preeclampsia, excess soluble endoglin is released from the placenta into the circulation and that it may then synergize with sFlt1, which binds PlGF and vascular endothelial growth factor to cause endothelial dysfunction, he explained. Women in this analysis with high levels of either sEng or sFlt1—but not both—had small elevations in preeclampsia risk.

Recommended Reading

'Do the Logical Thing' in Managing Preeclampsia
MDedge ObGyn
Medicolegal Issues in Preterm Birth of Multiples
MDedge ObGyn
AFP Testing Is Expensive, Now Largely Obsolete
MDedge ObGyn
Herpes Hepatitis: Timely Diagnosis Can Be Lifesaving
MDedge ObGyn
Antiretroviral Timing in Pregnancy Is Tricky
MDedge ObGyn
Expedite Assessment of Postpartum Blood Loss
MDedge ObGyn
Fetal Lung Volume Gain With FETO 'Impressive'
MDedge ObGyn
Canada to Supply Varicella Postexposure Prophylaxis
MDedge ObGyn
Bleeding, Pathogens Combined Increase Risk of Preterm Birth
MDedge ObGyn
Safe, efficient management of acute asthma
MDedge ObGyn